In a recent study of patients with atrial fibrillation, dabigatran (Pradaxa), was linked to a lower incidence of recurrent bleeding. Dabigatran is an anticoagulant used to lower the chance of stroke and blood clots that may be caused by atrial fibrillation. It works by blocking a clotting agent in the blood, called thrombin. Researchers of this study observed 1,539 patients with atrial fibrillation who experienced a major bleeding event while taking either dabigatran or warfarin, another anticoagulant. When all patients were compared, those who stopped taking anticoagulants after their bleeding event had a higher risk of stroke or death. When dabigatran and warfarin were compared, those who resumed dabigatran were less likely to have another major bleeding event as those who were taking warfarin.
Atrial fibrillation is an irregular heartbeat. It may develop from high blood pressure or heart disease. Symptoms of atrial fibrillation include dizziness, weakness, and tiredness.